# B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

> **NCT03332121** · PHASE1 · COMPLETED · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 30 (actual)

## Conditions studied

- CD20 Positive B Cell Non-Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** B001

## Key facts

- **NCT ID:** NCT03332121
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-22
- **Primary completion:** 2020-11-30
- **Final completion:** 2021-02-28
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332121, "B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03332121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*